[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100554855":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":13,"locations":21,"responsibleParty":39,"collaborators":7,"id":41,"slug":42,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":7,"eligibilityCriteria":46,"healthyVolunteers":43,"sex":47,"minAge":7,"maxAge":7,"enrollmentInfo":48,"targetDuration":7,"studyType":51,"phases":7,"briefSummary":52,"conditions":53,"keywords":57,"overallStatus":24,"whyStopped":7,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},{"fullName":5,"class":6},"NHS Greater Glasgow and Clyde","OTHER",null,[9],{"name":10,"affiliation":11,"role":12},"Andreas Brunklaus, MD PhD","NHS Greater Glasgow & Clyde","PRINCIPAL_INVESTIGATOR",[14,19],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Kirsty Hendry, PhD","CONTACT","0141 451 5888","SCN1AHorizons@glasgow.ac.uk",{"name":10,"role":16,"phone":17,"phoneExt":7,"email":20},"andreas.brunklaus@glasgow.ac.uk",[22],{"facility":23,"status":24,"city":25,"state":7,"zip":26,"country":27,"countryCode":28,"cosmosGeoPoint":29,"geoPoint":34,"contacts":35},"Royal Hospital for Children","RECRUITING","Glasgow","G51 4TF","United Kingdom","UK",{"type":30,"coordinates":31},"Point",[32,33],-4.25763,55.86515,{"lat":33,"lon":32},[36],{"name":15,"role":16,"phone":37,"phoneExt":7,"email":38},"0141 4515888","kirsty.hendry@glasgow.ac.uk",{"type":40,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100554855","scn1a-horizons-a-natural-history-study-of-scn1a-related-epilepsies-in-the-united-kingdom-100554855",false,"NCT06504511","SCN1A Horizons A Natural History Study of SCN1A-related Epilepsies in the United Kingdom","Patients meeting the following inclusion criteria will be considered eligible for this study:\n\n1. Patient and\u002For legally authorised representative must be willing and able to give informed consent\u002Fassent for participation in the study.\n2. Patient and parent\u002Fcaregiver are willing and able (in the Investigator's opinion) to comply with all study requirements (including ability and willingness to comply with virtual visits).\n3. Participant has a confirmed pathogenic (class 5) or likely pathogenic (class 4. SCN1A variant, as demonstrated by genetic testing.\n\nExclusion criteria:\n\nPatient has any other significant disease or disorder which, in the opinion of the Investigator, may either put the patient at risk because of participation in the study, or may affect the patient's ability to participate in the study.","ALL",{"count":49,"type":50},400,"ESTIMATED","OBSERVATIONAL","The aims of this prospective natural history study are to define the seizure, neuro-developmental, and behavioural characteristics of SCN1A-related epilepsies\u002FDravet syndrome in children and adults longitudinally over a period of three years. In addition, this study will compare missense and truncating genotypes in terms of i) rates of change of countable convulsive seizures per month and ii) neurodevelopmental outcome and trajectories.",[54,55,56],"SCN1A","Dravet Syndrome","Epilepsy",[56,54,58,59],"Natural History","Developmental Outcome","2024-07-15",{"date":62,"type":63},"2024-07-16","ACTUAL",{"date":65,"type":63},"2023-11-20",{"date":67,"type":50},"2026-06-01",{"name":5,"class":6},1]